NEMLUVIO Market Summary

Key Factors Driving NEMLUVIO Growth

1. First-in-Class IL-31 Mechanism Addresses the Core Driver of Itch

Unlike biologics that primarily target type 2 inflammation, NEMLUVIO directly blocks IL-31 signaling, a pathway strongly associated with chronic pruritus. This differentiated mechanism is particularly important because itch remains one of the most burdensome symptoms in both PN and AD.

In the pivotal OLYMPIA studies, substantial reductions in itch were observed as early as week 4, supporting a clinically meaningful differentiation in a market where rapid itch control is highly valued by physicians and patients.

2. Dual Approved Indications Expand the Addressable Market

NEMLUVIO has secured approvals in both:

• Prurigo Nodularis (PN)
• Moderate-to-severe Atopic Dermatitis (AD)

This dual-indication strategy significantly expands the commercial opportunity.

Atopic dermatitis alone affects approximately 16.5 million adults in the United States, with several million patients classified as having moderate-to-severe disease. Meanwhile, PN is a rare but severely debilitating disease with substantial unmet need and historically limited treatment options. The ability to commercialize across both indications creates a larger and more diversified revenue base.

3. Strong Phase III Efficacy Supports Rapid Physician Adoption

In the Phase III ARCADIA program for atopic dermatitis:

• Significant improvements in EASI scores were achieved.
• Clinically meaningful itch reductions were observed.
• Responses were maintained through long-term extension studies.

In PN, the OLYMPIA 1 and 2 studies demonstrated statistically significant improvements in both itch severity and skin lesion clearance compared with placebo. These data provide a strong foundation for dermatology adoption and reimbursement discussions.

4. Favorable Dosing and Patient Convenience

NEMLUVIO is administered as a subcutaneous injection every four weeks following loading doses. Less frequent dosing compared with some biologics may improve patient adherence and persistence.

Long-term dermatology markets are heavily influenced by convenience and treatment burden, making monthly maintenance dosing a potentially important commercial advantage. Galderma has emphasized ease of administration and patient support programs as key components of its launch strategy.

5. Large Opportunity in Patients with Residual Itch Despite Existing Biologics

Although biologics such as Dupixent have transformed AD treatment, many patients continue to experience persistent itching despite adequate control of skin inflammation.

Because NEMLUVIO directly targets the itch pathway, dermatologists may increasingly consider it for patients whose primary complaint remains uncontrolled pruritus. This creates a substantial opportunity beyond biologic-naïve patients and may support switching or sequencing strategies in clinical practice. Published studies have consistently identified chronic itch as one of the largest unmet needs in AD management.

NEMLUVIO Recent Developments

In January 2026, Galderma Canada has announced the Health Canada authorization of NEMLUVIO (nemolizumab), a first-in-class biologic treatment for both moderate-to-severe atopic dermatitis and prurigo nodularis. NEMLUVIO was granted authorization for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Furthermore, NEMLUVIO was granted authorization for the treatment of adults with moderate-to-severe prurigo nodularis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

“NEMLUVIO Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of NEMLUVIO for approved indication like Atopic dermatitis, Prurigo nodularis, and Pruritus; as well as potential indication like Scleroderma and Systemic scleroderma in the 7MM. A detailed picture of NEMLUVIO’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the NEMLUVIO for approved and potential indications. The NEMLUVIO market report provides insights about NEMLUVIO’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current NEMLUVIO performance, future market assessments inclusive of the NEMLUVIO market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of NEMLUVIO sales forecasts, along with factors driving its market.

NEMLUVIO Drug Summary

NEMLUVIO (nemolizumab) is a humanized monoclonal antibody developed by Galderma that targets the interleukin-31 receptor alpha (IL-31RA), thereby inhibiting IL-31 signaling, a key driver of itch, inflammation, and skin barrier dysfunction in atopic diseases. Administered as a subcutaneous injection, NEMLUVIO is approved for the treatment of moderate-to-severe Atopic Dermatitis and Prurigo Nodularis in appropriate patient populations. By specifically blocking the IL-31 pathway, the therapy rapidly reduces pruritus while improving skin lesions, sleep disturbance, and overall quality of life. Clinical trials have demonstrated significant improvements in itch severity and disease activity, both as monotherapy and in combination with topical treatments, establishing NEMLUVIO as a differentiated biologic option for patients with chronic inflammatory skin diseases characterized by severe itching. The report provides NEMLUVIO’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the NEMLUVIO Market Report

The report provides insights into:

• A comprehensive product overview including the NEMLUVIO MoA, description, dosage and administration, research and development activities in approved indications like Atopic dermatitis, Prurigo nodularis, and Pruritus; as well as potential indication like Scleroderma and Systemic scleroderma.
• Elaborated details on NEMLUVIO regulatory milestones and other development activities have been provided in NEMLUVIO market report.
• The report also highlights NEMLUVIO‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The NEMLUVIO market report also covers the patents information, generic entry and impact on cost cut.
• The NEMLUVIO market report contains current and forecasted NEMLUVIO sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The NEMLUVIO market report also features the SWOT analysis with analyst views for NEMLUVIO in approved and potential indications.

Methodology

The NEMLUVIO market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NEMLUVIO Analytical Perspective by DelveInsight

• In-depth NEMLUVIO Market Assessment

This NEMLUVIO sales market forecast report provides a detailed market assessment of NEMLUVIO for approved indication like Atopic dermatitis, Prurigo nodularis, and Pruritus; as well as potential indication like Scleroderma and Systemic scleroderma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted NEMLUVIO sales data uptil 2034.

• NEMLUVIO Clinical Assessment

The NEMLUVIO market report provides the clinical trials information of NEMLUVIO for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

NEMLUVIO Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

NEMLUVIO Market Potential & Revenue Forecast

• Projected market size for the NEMLUVIO and its key indications
• Estimated NEMLUVIO sales potential (NEMLUVIO peak sales forecasts)
• NEMLUVIO Pricing strategies and reimbursement landscape

NEMLUVIO Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• NEMLUVIO Market positioning compared to existing treatments
• NEMLUVIO Strengths & weaknesses relative to competitors

NEMLUVIO Regulatory & Commercial Milestones

• NEMLUVIO Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

NEMLUVIO Clinical Differentiation

• NEMLUVIO Efficacy & safety advantages over existing drugs
• NEMLUVIO Unique selling points

NEMLUVIO Market Report Highlights

• In the coming years, the NEMLUVIO market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The NEMLUVIO companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence NEMLUVIO’s dominance.
• Other emerging products for Atopic dermatitis, Prurigo nodularis, and Pruritus; as well as potential indication like Scleroderma and Systemic scleroderma are expected to give tough market competition to NEMLUVIO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of NEMLUVIO in approved and potential indications.
• Analyse NEMLUVIO cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted NEMLUVIO sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of NEMLUVIO in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of NEMLUVIO? How strong is NEMLUVIO’s clinical and commercial performance?
• What is NEMLUVIO’s clinical trial status in each individual indications such as Atopic dermatitis, Prurigo nodularis, and Pruritus; as well as potential indication like Scleroderma and Systemic scleroderma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NEMLUVIO Manufacturers?
• What are the key designations that have been granted to NEMLUVIO for approved and potential indications? How are they going to impact NEMLUVIO’s penetration in various geographies?
• What is the current and forecasted NEMLUVIO market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of NEMLUVIO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to NEMLUVIO for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is NEMLUVIO? What is the duration of therapy and what are the geographical variations in cost per patient?